XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Details)
 1 Months Ended 3 Months Ended
Jan. 31, 2025
USD ($)
May 31, 2023
USD ($)
Aug. 31, 2022
USD ($)
product
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2016
USD ($)
product
Mar. 31, 2025
USD ($)
shares
Sep. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
shares
Loss Contingencies [Line Items]                  
Common stock shares issued (in shares) | shares           71,109,514     71,009,866
Prepaid expenses and other current assets           $ 2,925,000     $ 2,865,000
Research and development           6,659,000   $ 10,397,000  
Loss contingency, loss in period             $ 1,800,000    
Gain on recovery of fraudulent funds transfer $ 1,800,000         $ 1,800,000   0  
Gensaic, Inc                  
Loss Contingencies [Line Items]                  
Payments to acquire investment     $ 5,100,000            
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Loss Contingencies [Line Items]                  
Advance written notice required to terminate agreement           90 days      
Northwestern University | License Agreement                  
Loss Contingencies [Line Items]                  
Upfront non-creditable one-time license issuance fee payment         $ 75,000        
Annual license maintenance fee payable         20,000        
Consideration payable for rights grant         $ 5,300,000        
Royalty obligation period         10 years        
Minimum number of product covered under license agreement | product         1        
AstraZeneca                  
Loss Contingencies [Line Items]                  
Upfront cash payment       $ 5,000,000          
Common stock shares issued (in shares) | shares       7,300,000          
Days immediately preceding the execution date       30 days          
License agreement milestone payments (up to)       $ 203,000,000          
First payment due upon completion of first phase       $ 3,000,000          
Gensaic, Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Loss Contingencies [Line Items]                  
License agreement milestone payments (up to)     452,000,000            
Research plan and budget, expected costs   $ 3,500,000 $ 3,000,000            
Prepaid expenses and other current assets           $ 1,000,000     $ 1,000,000
Research and development           $ 0   $ 600,000  
Developmental milestone approvals, number of products (at least) | product     3